Decreased accumulation of [14C]carboplatin in human cisplatin- resistant cells results from reduced energy-dependent uptake

Journal of Cellular Physiology

Volumn 183, Issue 1, 2000, Pages 108-116

  Shen, Ding Wu ^a   Goldenberg, Sarah ^a   Pastan, Ira ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC ACID; ARSENIC TRIOXIDE; CARBON 14; CARBOPLATIN; CISPLATIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CARBON; RHODAMINE 123; UNCOUPLING PROTEIN;

ARTICLE; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG SENSITIVITY; DRUG UPTAKE; HUMAN; HUMAN CELL; LIVER CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TEMPERATURE DEPENDENCE; CELL CULTURE; CELL MEMBRANE; CELL STRAIN KB; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; ENERGY METABOLISM; KINETICS; LIVER TUMOR; METABOLISM; MITOCHONDRION; MULTIDRUG RESISTANCE; PHYSIOLOGY; TEMPERATURE; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CARBOPLATIN; CELL MEMBRANE; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; HUMANS; KB CELLS; KINETICS; LIVER NEOPLASMS; MITOCHONDRIA; RHODAMINE 123; TEMPERATURE; TUMOR CELLS, CULTURED; UNCOUPLING AGENTS;

EID: 0033621774     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200004)183:1<108::AID-JCP13>3.0.CO;2-4     Document Type: Article

References (58)

1. Andrews PA, Jones JA, Varki NM, Howell SB. 1990. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2:93-100.
2. Anghileri LJ, Thouvenot P. 1997. Non-transferrin-bound iron and tumor cells. Anticancer Res 17:2529-2533.
3. Basu A, Weixel K, Saijo N. 1996. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell Growth Differ 7:1507-1512.
4. Berger W, Elbling L, Hauptmann E, Micksche M. 1997. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73: 84-93.
5. Chen ZS, Mutoh M, Sumizawa T, Furukawa T, Haraguchi M, Tani A, Saijo N, Kondo T, Akiyama S-I. 1998. An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells. Exp Cell Res 240:312-320.
6. Chu G. 1994. Cellular responses to cisplatin. The role of DNA-binding proteins and DNA repair. J Biol Chem 269:787-790.
7. Chuman Y, Chen ZS, Sumizawa T, Furukawa T, Haraguchi M, Takebayashi Y, Niwa K, Yamada K, Aikou T, Akiyama S. 1996. Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Biochem Biophys Res Commun 226:158-165.
8. Clugston CK, McLaughlin K, Kenny MK, Brown R. 1992. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum(II) Cancer Res 52:6375-6379.
9. Cornwell MM, Tsuruo T, Gottesman MM, Pastan I. 1987. ATP-binding properties of P-glycoprotein from multidrug-resistant KB cells FASEB J 1:51-54.
10. DeFeudis P, D'Incalci M, Broggini M. 1996. Block of bcr-abl expression and induction of apoptosis by cis-platinum in a human chronic myeloid leukemia cell line. Apoptosis 1:161-166.
11. Fanidi A, Harrington EA, Evan GI. 1993. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556.
12. Fink D, Aebi S, Howell SB. 1998. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4:1-6.
13. Fujii R-i, Mutoh M, Niwa K, Yamada K, Aikou T, Nakagawa M, Kuwano M, Akiyama S-i. 1994. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85:426-433.
14. Funato T, Ishii T, Kanbe M, Scanlon KJ, Sasaki T. 1997. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme. In Vivo 11:217-220.
15. Gately DP, Howell SB. 1993. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67:1171-1176.
16. Godwin AK, Meister A, Anderson ME. 1992. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070-3074.
17. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. 1995. Genetic analysis of the multidrug transporter. Annu Rev Genet 29:607-649.
18. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deely RG. 1994. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361.
19. Gutierrez JA, Yu J, Rivera S, Wessling-Resnick M. 1997. Functional expression cloning and characterization of SFT, a stimulator of Fe transport. J Cell Biol 139:895-905.
20. Hamaguchi K, Godwin AL, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC. 1993. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53:5225-5232.
21. Hettinga JV, Lemstra W, Meijer C, Los G, de Vries EG, Konings AW, Kampinga HH. 1996. Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. Int J Cancer 67:800-807.
22. Husain A, He G, Venkatraman ES, Spriggs DR. 1998. BRCA1 up-regulation is associated with repair-mediated resistance to cisdiamminedichloro-platinum(II). Cancer Res 58:1120-1123.
23. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT. 1996. Coordinated induction of MRP/GS-X pump and gamma-glutamyl-cysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271:14981-14988.
24. Jekunen AP, Hom DK, Alcaraz JE, Eastman A, Howell SB. 1994. Cellular pharmacology of dichloro(ethlenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells Cancer Res 54:2680-2687.
25. Johnson SW, Shen DW, Pastan I, Gottesman MM, Hamilton TC. 1996. Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 226:133-139.
26. Kelly SL, Basu A, Ticher BA, Hacker MP, Hamer DH, Lazo JS. 1988. Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-1815.
27. Keppler D, Konig J, Buchler M. 1997. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv Enzyme Regul 37:321-333.
28. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B, Barnett GH. 1996. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 13:1279-1285.
29. Kondo Y, Kuo SM, Watkin SC, Lazo JS. 1995. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 55:474-477.
30. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
31. Lai SL, Hwang J, Perng RP, Whang-Peng J. 1995 Modulation of cisplatin resistance in acquired-resistant non small cell lung cancer cells. Oncol Res 7:31-38.
32. Liu B, Cvijic ME, Jetzt A, Chin KV. 1996. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants. Cell Growth Differ 7:1105-1112.
33. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. 1992. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66:1109-1115.
34. Lowe SW, Ruley HE, Jacks T, Housman DE. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
35. Ma J, Maliepaard M, Kolker HJ, Verweij J, Schellens JH. 1998. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother Pharmacol 41:186-192.
36. Mann SC, Andrews PA, Howell SB. 1990. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25:236-240.
37. Melvik JE, Dornish JM, Pettersen EO. 1992. The binding of cisdichlorodiammine-platinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. Br J Cancer 66:260-265.
38. Minn AJ, Rudin CM, Boise LH, Thompson CB. 1995. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903-1910.
39. Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR. 1992. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro-(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res 52:6188-6193.
40. Moscow JA, Cowan KH. 1988. Multidrug resistance. J Natl Cancer Inst 80:14-20.
41. Naredi P, Heath DD, Enns RE, Howell SB. 1994. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. Cancer Res 54:6464-6468.
42. Parkes JG, Randell EW, Olivieri NF, Templeton DM. 1995. Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. Biochim Biophys Acta 1243:373-380.
43. Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR. 1996. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1857-1862.
44. Rischin D, Ling V. 1996. Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum(II). Br J Cancer 74:590-596.
45. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T. 1996. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 51:1855-1865.
46. Rosowsky A, Wright JE, Cucchi CA, Flatow JL, Trites DH, Teicher BA, Frei E. 1987. Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II). Cancer Res 47:5913-5918.
47. Ruan S, Okcu MF, Reb JP, Chiao P, Andreeff M, Levin V, Zhang W. 1998. Overexpressed WAS1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 58:1538-1543.
48. Sharp SY, Smith V, Hobbs S, Kelland LR. 1998. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines. Br J Cancer 78:175-180.
49. Shen DW, Akiyama S-i, Schoenlein P, Pastan I, Gottesman MM. 1995. Characterization of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 71:676-683.
50. Shen DW, Pastan I, Gottesman MM. 1998. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58:268-275.
51. Stein WD, Cardarelli C, Pastan I, Gottesman MM. 1994. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45:763-772.
52. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S-I, Kuwano M. 1996. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124-4129.
53. Wang Z, Lee KB, Reed E, Sinha BK. 1996. Sensitization by interleukin-1 alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo. Int J Cancer 68:583-588.
54. Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB, Knuutila S. 1997. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 18:286-291.
55. Welters MJ, Fichtinger-Schepman AM, Baan RA, Flens MJ, Scheper RJ, Braakhuis BJ. 1998. Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines. Br J Cancer 77:556-561.
56. Yotsuyanagi T, Ohta N, Futo T, Ito S, Chen DN, Ikeda K. 1991. Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfain binding. Chem Pharm Bull (Tokyo) 39:3003-3006.
57. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Panlusma C, Oude Elferink RP, Baas F, Borst P. 1995. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92:7690-7694.
58. Zhen W, Lind CJ, O'Connor PM, Reed E, Parker R, Howell SB, Bohor VA. 1992. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12:3689-3698.